Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19976836 | 0.91 | MAPK1 (0.41) | GSK3BCYP1A2HDAC6MAPK1ALPL | |
| SCHEMBL19976776 | 0.90 | GSK3B (0.48) | GSK3BCYP1A2HDAC6MAPK1DYRK1A | |
| SCHEMBL19976866 | 0.87 | DYRK1A (0.42) | GSK3BCYP1A2MAPK1CDK1CDK2 | |
| SCHEMBL19976846 | 0.86 | KDM4E (0.42) | GSK3BHDAC6MAPK1CDK1CDK2 | |
| SCHEMBL19976758 | 0.84 | DYRK1A (0.40) | HDAC6MAPK1ALPLLMNADYRK1A | |
| SCHEMBL19976854 | 0.84 | GSK3B (0.42) | GSK3BHDAC6MAPK1LMNACDK1 | |
| SCHEMBL19976767 | 0.84 | GSK3B (0.51) | GSK3BCYP1A2HDAC6MAPK1LMNA | |
| SCHEMBL19976729 | 0.84 | HDAC6 (0.49) | GSK3BHDAC6MAPK1 | |
| SCHEMBL19976857 | 0.82 | MAPK1 (0.35) | GSK3BHDAC6MAPK1LMNACDK1 | |
| SCHEMBL19976766 | 0.82 | ABL1 (0.43) | GSK3BHDAC6MAPK1LMNACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920012-B2 | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |